Advertisement

Topics

Alnylam Pharmaceuticals und Medison Pharma kooperieren bei der Vermarktung von RNAi-Therapeutika in Israel

12:55 EST 21 Jan 2019 | FinanzNachrichten

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), das führende Unternehmen für RNAi-Therapeutika, und Medison Pharma, Israels führender kommerzieller Partner für innovative Arzneimittel, gaben heute d...

Original Article: Alnylam Pharmaceuticals und Medison Pharma kooperieren bei der Vermarktung von RNAi-Therapeutika in Israel

NEXT ARTICLE

More From BioPortfolio on "Alnylam Pharmaceuticals und Medison Pharma kooperieren bei der Vermarktung von RNAi-Therapeutika in Israel"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...